Obagi Medical Partners with Alpha Aesthetic for Real-World Evidence Study on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Alpha Aesthetic Partners for the ALOHA Program to evaluate Obagi® saypha® MagIQ™ across its network.
- Alpha was selected for its commitment to innovation and scalable care models in aesthetic medicine.
- The program will collect standardized data on clinical performance and patient experience, with initial findings presented at the Alpha Summit.
- Obagi® saypha® MagIQ™ is Obagi’s first FDA-approved injectable hyaluronic acid filler, developed by Croma-Pharma GmbH.
The big picture
This collaboration underscores the growing emphasis on real-world evidence in the aesthetic medicine sector, particularly for new injectable products. Waldencast plc is leveraging strategic partnerships to drive innovation and scale within its beauty and wellness portfolio. The ALOHA Program could set a precedent for how physician-dispensed skincare brands validate their offerings through structured, multi-site evaluations.
What we're watching
- Clinical Validation
- How the real-world evidence from the ALOHA Program will impact the adoption of saypha® MagIQ™ in diverse clinical environments.
- Market Expansion
- Whether Alpha Aesthetic Partners' network can accelerate the commercialization of Obagi’s injectable hyaluronic acid filler.
- Competitive Positioning
- The pace at which Obagi Medical can differentiate saypha® MagIQ™ in a crowded aesthetic injectables market.
Related topics